154 related articles for article (PubMed ID: 2129419)
1. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
Gillies SD; Wesolowski JS
Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
[TBL] [Abstract][Full Text] [Related]
2. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
[TBL] [Abstract][Full Text] [Related]
4. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities.
Robinson RR; Chartier J; Chang CP; Horwitz AH; Better M
Hum Antibodies Hybridomas; 1991 Apr; 2(2):84-93. PubMed ID: 1873500
[TBL] [Abstract][Full Text] [Related]
5. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
6. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
7. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
8. The construction of a mouse/human chimeric antibody against human breast cancer cells.
Meulemans E; Vandevyver C; Volckaert G; Raus J
Year Immunol; 1993; 7():131-6. PubMed ID: 8372502
[No Abstract] [Full Text] [Related]
9. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
10. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.
Liu AY; Robinson RR; Murray ED; Ledbetter JA; Hellström I; Hellström KE
J Immunol; 1987 Nov; 139(10):3521-6. PubMed ID: 3119711
[TBL] [Abstract][Full Text] [Related]
11. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
[TBL] [Abstract][Full Text] [Related]
12. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
13. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
14. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
16. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
17. Recombinant mouse/human chimeric anti-colorectal carcinoma antibody cACT19.
Xiang J; Moyana T; Liu E
Hum Antibodies Hybridomas; 1994; 5(3-4):105-15. PubMed ID: 7756575
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).
Hutzell P; Kashmiri S; Colcher D; Primus FJ; Hand PH; Roselli M; Finch M; Yarranton G; Bodmer M; Whittle N
Cancer Res; 1991 Jan; 51(1):181-9. PubMed ID: 1988082
[TBL] [Abstract][Full Text] [Related]
19. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
20. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing.
Kaulen H; Seemann G; Bosslet K; Schwaeble W; Dippold W
Year Immunol; 1993; 7():106-9. PubMed ID: 8372499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
